{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:53:36Z","timestamp":1785920016165,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016282","name":"MEI Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016282","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Surface Oncology"},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Verastem"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016796","name":"Adaptive Biotechnologies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016796","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ascentage Pharma"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100016282","name":"MEI Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016282","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Syros Pharmaceuticals"},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Verastem"},{"name":"Zentalis"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jansen"},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clinthera.2020.08.017","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T02:17:43Z","timestamp":1601950663000},"page":"1955-1974.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Waweru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-3888","authenticated-orcid":false,"given":"Pauline","family":"Le Nouveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Padhiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-5578","authenticated-orcid":false,"given":"Gautamjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.08.017_bib1","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib2","first-page":"185","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J\u00a0Natl Compr Canc Ne"},{"key":"10.1016\/j.clinthera.2020.08.017_bib3","series-title":"SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia","year":"2019"},{"key":"10.1016\/j.clinthera.2020.08.017_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.017_bib6","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.017_bib7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.017_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinthera.2020.08.017_bib9","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2020.08.017_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in\u00a0vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2020.08.017_bib11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.017_bib12","series-title":"Project Orbis: FDA Approves Acalabrutinib for CLL and SLL","year":"2019"},{"key":"10.1016\/j.clinthera.2020.08.017_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2020.08.017_bib14","series-title":"Systematic Reviews","year":"2008"},{"key":"10.1016\/j.clinthera.2020.08.017_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med"},{"key":"10.1016\/j.clinthera.2020.08.017_bib16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2020.08.017_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2020.08.017_bib19","series-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"10.1016\/j.clinthera.2020.08.017_bib20","series-title":"NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias, and Bias-Adjustment","author":"Dias","year":"2011"},{"key":"10.1016\/j.clinthera.2020.08.017_bib21","series-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"10.1016\/j.clinthera.2020.08.017_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib24","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.3324\/haematol.2019.223743","article-title":"A\u00a0cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"105","author":"Tedeschi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2020.08.017_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41408-018-0131-2","article-title":"Chronic lymphocytic leukemia treatment algorithm 2018","volume":"8","author":"Parikh","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2020.08.017_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720912990","article-title":"BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-na\u00efve elderly patients with CLL","volume":"11","author":"Rogers","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/cer-2017-0086","article-title":"Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"7","author":"Xu","year":"2018","journal-title":"J\u00a0Comp Effect Res"},{"key":"10.1016\/j.clinthera.2020.08.017_bib28","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s12325-016-0398-2","article-title":"A\u00a0systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia","volume":"33","author":"Stadler","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2020.08.017_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","article-title":"A\u00a0network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia","volume":"41","author":"Ladyzynski","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2020.08.017_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial","volume":"159","author":"Wu","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13643-015-0133-0","article-title":"Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities","volume":"4","author":"Cameron","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinthera.2020.08.017_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2012.10.019","article-title":"Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models","volume":"16","author":"Cope","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2020.08.017_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2020.08.017_bib34","series-title":"NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data","author":"Latimer","year":"2011"},{"issue":"35","key":"10.1016\/j.clinthera.2020.08.017_bib35","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clinthera.2020.08.017_bib36","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"New Engl J Med"},{"issue":"9980","key":"10.1016\/j.clinthera.2020.08.017_bib37","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clinthera.2020.08.017_bib38","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:48Z","timestamp":1758963348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820304239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0149291820304239"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}